Appendix A. Motor Neuron Disease and ALS Diagnosis Codes

|  |  |  |  |
| --- | --- | --- | --- |
| **ICD-9-CM Code** | **Description** | **ICD-10-CM Code** | **Description** |
| 335.20 | Amyotrophic lateral sclerosis | ‘G12.21' | Amyotrophic lateral sclerosis |
| 335.21 | Progressive muscular atrophy |
| 335.22 | Progressive bulbar palsy | 'G12.22' | Progressive bulbar palsy |
| 335.23 | Pseudobulbar palsy | 'G12.8' | Other spinal muscular atrophies and related syndromes |
| 335.24 | Primary lateral sclerosis | 'G12.29' | Other motor neuron disease |
| 335.29 | Other motor neuron disease |

Appendix B. Administrative claims algorithm to identify patients with ALS

|  |  |
| --- | --- |
| **ALS** | **Not ALS** |
| An encounter claim for ALS ≥ 1 year + evidence of deatha or prescription for riluzole | No ALS encounter claim and no prescription for riluzole |
| *OR* | *OR* |
| An encounter claim for ALS ≥ 2 years + neurologist visit | An encounter claim for ALS in 1 year and no neurologist visit |
| *OR* | *OR* |
| Age < 65, an encounter claim for ALS + neurologist visit | Age < 18 |
| *OR* | *OR* |
| A visit for ALS in 1 year and ≥ 5 neurologist visits | Evidence of death only |

ALS, amyotrophic lateral sclerosis

aNotification from Centers for Medicare and Medicaid Services; could not verify ALS diagnosis on death certificate

Note: Patients not classified into either group due to not having both requirements where necessary were considered “possible ALS”

ALS, amyotrophic lateral sclerosis; MAPD, Medicare Advantage Prescription Dru**g**